(S (NP (NP (NNP Hydroxyurea)) (PRN (-LRB- -LRB-) (NP (NNP HU)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG alleviating) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Sickle) (NNP Cell) (NNP Anemia) (NN disease)))))))))))))) (. .))
(S (SBAR (IN While) (S (NP (NNP Hydroxyurea)) (VP (VBZ reduces) (NP (NP (DT the) (NNS complications)) (VP (VBN associated) (PP (IN with) (NP (NNP Sickle) (NNP Cell) (NNP Anemia))))) (PP (IN in) (NP (DT some) (NNS patients)))))) (, ,) (NP (NNS others)) (VP (VBP do) (RB not) (VP (VP (VB benefit) (PP (IN from) (NP (DT this) (NN drug)))) (CC and) (VP (NN experience) (NP (JJ deleterious) (NNS effects))) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ is) (ADVP (RB also)) (NP (DT a) (JJ chemotherapeutic) (NN agent))))))) (. .))
(SINV (ADVP (RB Therefore)) (S (, ,) (WHPP (TO to) (WHNP (WP whom))) (, ,) (SQ (MD should) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP HU)))) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (DT a) (JJ viable) (NN option)))))) (, ,)) (VBZ is) (NP (NP (DT the) (JJ main) (NN question)) (VP (VBN asked) (PP (IN by) (NP (DT the) (JJ responsible) (NN physician))))) (. .))
(S (NP (PRP We)) (VP (VBP address) (NP (DT this) (NN question)) (PP (IN by) (S (VP (VBG developing) (NP (NP (VBG modeling) (NNS techniques)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VP (VB predict) (NP (NP (NP (DT a) (NN patient) (POS 's)) (NN response)) (PP (TO to) (NP (NNP HU))))) (CC and) (ADVP (RB therefore)) (VP (JJ spare) (NP (DT the) (JJ non-responsive) (NNS patients)) (PP (IN from) (NP (NP (DT the) (JJ unnecessary) (NNS effects)) (PP (IN of) (NP (NNP HU))) (PP (IN on) (NP (NP (DT the) (NNS values)) (PP (IN of) (NP (NP (CD 22) (NNS parameters)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN obtained) (PP (IN from) (NP (NP (NN blood) (NNS samples)) (PP (IN in) (NP (CD 122) (NNS patients)))))))))))))))))))))))))) (. .))
(S (S (VP (VBG Using) (NP (DT this) (NN data)))) (, ,) (NP (PRP we)) (VP (VBD developed) (NP (NP (NNP Deep) (NNP Artificial) (NNP Neural) (NNP Network) (NNS models)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB predict) (PP (IN with) (NP (ADJP (CD 92.6) (NN %)) (NN accuracy))) (, ,) (NP (NP (DT the) (JJ final) (NNP HbF) (NN value)) (PP (IN of) (NP (DT a) (NN subject))) (PP (IN after) (S (VP (VBG undergoing) (NP (NNP HU) (NN therapy)))))))))))) (. .))
(S (NP (PRP$ Our) (JJ current) (NNS studies)) (VP (VBP are) (VP (VBG focussing) (PP (IN on) (S (VP (VBG forecasting) (NP (NP (DT a) (NN patient) (POS 's)) (NNP HbF) (NN response)) (, ,) (ADVP (NP (CD 30) (NNS days)) (RB ahead) (PP (IN of) (NP (NN time))))))))) (. .))
